×

Henry Schein Announces the Availability of a Coronavirus 2019 (COVID-19) Point-of-Care Antibody Rapid Test

Posted on March 26, 2020

Henry Schein, Inc. (Nasdaq: HSIC) announced today the availability of an antibody rapid blood test, known as Standard Q COVID-19 IgM/IgG Rapid Test, intended to be administered at the point of care. The test delivers results within 15 minutes from a pinprick with no instrumentation required.

Health care professionals can use the results of the test, along with a patient’s medical history, symptoms, and results of other relevant testing, to make informed decisions about patient treatment and care.

Henry Schein is working through multiple channels to distribute the tests in the United States as quickly as possible in response to the urgent need for rapid, accurate testing. The Company anticipates having at least several hundred thousand tests available by March 30 and significantly increased availability beginning in April 2020.

The Standard Q COVID-19 test is a rapid immunochromatography test designed for the qualitative presumptive detection of specific IgM and IgG antibodies associated with the 2019 novel coronavirus (SARS-CoV-2) in blood drawn with a pinprick.

Because serology tests measure antibodies, they can help assess the likelihood of past as well as present infection, and are meant to be used as an aid to health care professionals in diagnosing the mid- to later stages of the viral infection. Along with other information, such as the presence of symptoms, the tests may help health care professionals assess whether individuals (including health care workers) have recovered from the virus. Follow-up testing with a molecular diagnostic should be considered to confirm or rule out infection.

The Standard Q COVID-19 IgM/IgG Rapid Test is being made available under emergency guidance issued by the U.S. Food and Drug Administration (FDA).

“Henry Schein is committed to providing health care professionals with quality products they can rely on to care for patients,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “Henry Schein has played a key role in providing point-of-care testing to health care professionals, and is now responding to the urgent need for wide availability of rapid point-of-care testing for COVID-19. This pandemic is an unprecedented situation, and making rapid diagnostic tools available to health care professionals is critical for detecting and mitigating the spread of the coronavirus.”

As the world’s largest distributor of health care solutions to office-based dental and medical professionals, Henry Schein is uniquely positioned to distribute the Standard Q COVID-19 test efficiently. Henry Schein plans to make the Standard Q COVID-19 test available for use by physician offices, hospitals, and other relevant health care institutions.

The distribution of the kit is part of Henry Schein’s continued efforts to address pandemic preparedness and response. Among other efforts, Henry Schein is in direct contact with the World Health Organization and other multilateral and domestic organizations as part of Henry Schein’s role as the private-sector lead of the Pandemic Supply Chain Network, a public-private partnership created in 2015 to improve the efficiency of the supply chain for personal protective equipment.

The Standard Q COVID-19 test is manufactured by SD Biosensor, Inc., a global bio-diagnostic company. SD BioSensor is represented by VelocityDX in the United States. Henry Schein intends to add other tests from VelocityDX and other suppliers specific to COVID-19, with the goal of offering a wide array of point-of-care tests for health care professionals.

A Q&A addressing the new test and providing additional information about it is available at www.henryschein.com/COVID19Statements.

For customers interested in more information about the Standard Q COVID-19 IgM/IgG Rapid Test, please contact Henry Schein at (844) 211-0140.

To learn more about what Henry Schein is doing to address this unprecedented situation and the actions the Company is taking to get more product into the hands of those who need it most – health care workers – please visit www.henryschein.com/COVID19update.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 19,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional healthcare clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items.

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 31 countries. The Company's sales from continuing operations reached $10.0 billion in 2019, and have grown at a compound annual rate of approximately 13 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.comFacebook.com/HenrySchein, and @HenrySchein on Twitter.

Cautionary Note Regarding Forward-Looking Statements

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate," “to be,” “to make,” “understand or understanding,” or other comparable terms. Forward looking statements include the number of tests intended to be made available and the timing for availability, the nature of the target market, as well as the efficacy or relative efficacy of the test results given that the test efficacy has not been independently verified under normal FDA procedures. A full discussion of our operations and financial condition, status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: effects of a highly competitive and consolidating market; increased competition by third party online commerce sites; our dependence on third parties for the manufacture and supply of our products; our dependence upon sales personnel, customers, suppliers and manufacturers; our dependence on our senior management; fluctuations in quarterly earnings; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers; general global macro-economic conditions; risks associated with currency fluctuations; risks associated with political and economic uncertainty; disruptions in financial markets; volatility of the market price of our common stock; changes in the health care industry; implementation of health care laws; failure to comply with regulatory requirements and data privacy laws; risks associated with our global operations; risks associated with the Novel Coronavirus Disease 2019 (COVID-19); risk associated with the United Kingdom's withdrawal from the European Union; transitional challenges associated with acquisitions, dispositions and joint ventures, including the failure to achieve anticipated synergies/benefits; financial and tax risks associated with acquisitions, dispositions and joint ventures; litigation risks; new or unanticipated litigation developments and the status of litigation matters; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence on third parties for certain technologically advanced components; risks from disruption to our information systems; cyberattacks or other privacy or data security breaches; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.







Align Technology Receives FDA 510(k) Clearance for the iTero Element 5D Imaging System in the U.S.

Posted on March 25, 2020

Seeing is believing: imaging and visualization capabilities of the iTero Element 5D Imaging System are designed to enable better patient engagement and lead to increased patient acceptance of recommended dental treatment

     • First intraoral scanner with near-infrared imaging (NIRI) technology that scans the internal structure of a tooth (enamel and dentin) in real time1.

     • First integrated dental imaging system that records 3D, intra-oral color and NIRI with a single scan, and enables comparison over time using iTero® TimeLapse1.

     • NIRI technology of the iTero Element® 5D system aids in detection and monitoring of interproximal caries lesions above the gingiva without using harmful radiation1.

Align Technology, Inc. (NASDAQ: ALGN) today announced that the U.S. Food and Drug Administration (FDA) has cleared the award winning iTero Element 5D Imaging System for commercial availability in the United States. The iTero Element 5D Imaging System expands the suite of existing high-precision, full-color imaging and fast scan times of the iTero Element intraoral scanner portfolio with a new clinical approach, optimized orthodontic and restorative dental workflows, and an improved doctor experience. In addition, iTero Element 5D Imaging System visualization tools improve patient engagement and communication by helping patients see and better understand their current dental health, their treatment plan options, and prescribed outcome on the iTero touchscreen, enabling better patient education, engagement, and compliance during treatment.

Commenting on today’s announcement, Yuval ShakedAlign Technology senior vice president and managing director, iTero scanner and services business said, “The iTero Element 5D Imaging System seamlessly combines three key scanning technologies (3D data, intra-oral color photos and NIRI images) into one, integrated scan, and we are excited to bring this advancement in intraoral scanner technology to the U.S. market to help doctors provide better oral care for their patients. At the same time, we are mindful of the current environment and the impact that the COVID-19 pandemic is having across the world, and are focused solely on customer education regarding this new technology while so many dental practices in the U.S. are operating on a limited schedule.”

iTero Element 5D Imaging System: better clinical care

The iTero Element 5D scanner is the first integrated dental imaging system that simultaneously records 3D, intra-oral color and NIRI images and enables comparison over time using iTero TimeLapse1. Integrated 3D, intra-oral color and NIRI technology of the iTero Element 5D Imaging System aids doctors in detecting and monitoring the progression of interproximal caries (cavities or tooth decay) above the gingiva without using harmful radiation1, thereby helping to ensure that their patients receive even better care with visualization, education, and treatment acceptance.

The diagnosis of carious lesions or “caries,” especially interproximal lesions or those between teeth, can be hampered by several factors, including variations in the shape and alignment of teeth, traditional limitations of X-ray examinations that include variability in exposure level, bad angulations in the captured image, or overlapping contacts in the image, among other factors. With the iTero Element 5D Imaging System, doctors can scan patients at each visit to view a patient’s progress over time and together view treatment options that result in clearer decisions for better clinical care.

A survey of doctors outside of the U.S. who had used the iTero Element 5D Imaging System for at least six months reported increases in interproximal caries detection, patient acceptance of treatment recommendations, and practice revenue.

More than just a scanner

With one full arch scan, completed in as little as 60 seconds2, the iTero Element 5D Imaging System provides doctors with powerful visualization capabilities, including:

     • NIRI (near infrared image)

     • Intraoral camera

     • 3D impressions for restorative and orthodontic work

     • Analysis instruments, such as the Occlusogram occlusal clearance tool

     • iTero TimeLapse technology

     • Invisalign® Outcome Simulator and Progress Assessment

The U.S. Patent and Trademark Office has recently issued two patents that cover the advanced features in iTero Element 5D Imaging System: patent no. 10,390,913, entitled “Diagnostic Intraoral Scanning” and patent no. 10,507,087, entitled “Methods and Apparatuses for Forming a Three-Dimensional Volumetric Model of a Subject’s Teeth.” Additional patents covering other innovations in the iTero Element 5D Imaging System are pending.

The iTero Element 5D Imaging System will be commercially available in the United States in the second quarter of 2020 and is currently available in Canada, Latin America, European Union (EU) countries and EU EFTA countries, the United Kingdom, Australia, New Zealand, Hong Kong, ThailandJapanKoreaSingapore and Taiwan.

¹Data on file at Align Technology, as of December 4, 2018.

2Data on file at Align Technology, as of February 10, 2017.

Information about the iTero Element 5D Imaging System can be found at https://www.itero.com/en/products/itero_element_5d.

For a complete list of U.S. patents covering the iTero family of scanners see www.aligntech.com/patents.

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, and iTero® intraoral scanners and services. Align’s products help dental professionals achieve the clinical results they expect and deliver effective, cutting-edge dental options to their patients. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com.

For additional information about iTero digital scanning system, please visit www.itero.com.

Forward Looking Statements

This press release contains forward-looking statements, including statements regarding the capabilities and performance of Align’s products, the timing of their availability including as a result of the COVID-19 pandemic.  These forward-looking statements are based on current expectations and estimates and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements should, therefore, be considered in light of various important factors, including, but not limited to the risk factors under the heading “Risk Factors” in the company’s annual report on Form 10-K for the year ended December 31, 2019, as updated by the company’s other filings with the Securities and Exchange Commission.  Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “could,” “should,” “would,” “targeted” and similar words and expressions are intended to identify forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Align undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.







LOCATOR® Overdenture Attachment System Enters the Digital Workflow with Scan Bodies

Posted on March 25, 2020

Zest Dental Solutions, the only manufacturer of the Zest LOCATOR® Family of Attachment Systems, provider of clinician trusted dental materials and small equipment, enters the digital workflow with the launch of abutment level Scan Bodies for LOCATOR®.

The Scan Body for the Zest LOCATOR Attachment System was designed to automatically create the exact dimension and undercut required to retain the LOCATOR denture attachment housing within a 3D printed or milled prosthesis. The precise location of the LOCATOR and implant are captured through the scan, either intraorally or in a lab setting, for easy case planning and design. The overdenture is then 3D Printed or milled with the recess for the LOCATOR housing, allowing for easy, and quicker pick-up.

“At Zest, we are always striving to deliver products and solutions that help clinicians practice smarter and provide better dentistry resulting in happy patients,” says Tom Stratton, CEO Zest Dental Solutions. “By bringing LOCATOR into the digital workflow, clinicians can save time while improving the accuracy and consistency of their overdenture cases.”

The LOCATOR Scan Bodies are made of a durable PEEK material which can be sterilized and reused. They are available for all LOCATOR Attachments Systems, including LOCATOR Root, LOCATOR abutments and LOCATOR abutments for LOCATOR Implants.

To learn more or to purchase Scan Bodies for the LOCATOR Attachment System visit https://www.zestdent.com or call 800-262-2310.

About Zest Dental Solutions

Zest Dental Solutions is a global leader in the design, development, manufacturing and distribution of diversified dental solutions for a continuum of patient care from the preservation of natural teeth to the treatment of total edentulism. The company's product offering consists of a range of solutions including the LOCATOR® Family of Attachment Systems, LOCATOR Implant Systems, Consumables and Dental Equipment, with global distribution through Implant Companies, dealer/distributor networks, as well as a domestic retail sales operation. Zest Dental Solutions is headquartered in Carlsbad, California with operations in Anaheim and Escondido, California. Zest Dental Solutions is a portfolio company of BC Partners, a leading private equity firm. For more information, please visit www.zestdent.com

 







AO Elects Dr. Clark M. Stanford as 34th President

Posted on March 24, 2020

Clark M. Stanford, DDS, PhD, MHA, prosthodontist and distinguished professor and dean, College of Dentistry, University of Illinois at Chicago, has been elected as the Academy of Osseointegration’s (AO) 34th president.

Dr. Stanford succeeds Jay P. Malmquist, DMD, from Portland, OR at the helm of the Academy.

Approval of the Academy’s 2020/21 slate of officers as submitted and approved by the AO Board of Directors was scheduled to occur at the Academy’s Annual Business Meeting on Saturday, March 21, 2020 in Seattle, WA. As a result of the cancellation of the Academy’s 35th Annual Meeting, the slate was instead presented for, and received, membership approval via electronic voting. This was conducted under Article V. Meeting of Members, Section 5 of the Academy’s bylaws.

A director on the board since 2010, one of Dr. Stanford's most significant contributions has been serving as chair of the Academy’s summits in 2014 and 2018.  During his time as a member since 1994, Dr. Stanford has also served as chair of the 2011 Mini Summit and White Paper task forces, and 2011 Sponsorship of Symposia, as well as a member of the Website Education, 2014 Mini-summit Planning, Finance and Audit, and AO/OF Research Grant committees.

A new at-large director and treasurer were among those elected to the Academy’s board of directors. Those included Lambert J. Stumpel, DDS, a general practitioner maintaining a private practice in San Francisco, CA as at-large director, and Joerg Neugebauer, DDS, PhD, an oral surgeon from Landsberg am Lech, Germany as treasurer, who has served as a director on the board since 2016. The full new slate of officers elected includes:

Officers

     • President: Clark M. Stanford, DDS, PhDMHA; AO Fellow, prosthodontist and distinguished professor and dean, College of Dentistry, University of Illinois at Chicago, IL;

     • President-elect: Tara L. Aghaloo, DDS, MD, PhD; AO Fellow, oral and maxillofacial surgeon, UCLA Medical Center from Los Angeles, CA;

     • Vice President: Amerian D. Sones, DMD, MS; AO Fellow, prosthodontist, and executive director, Continuing Education Texas A&M University, College of Dentistry in Dallas, TX;

     • Secretary: Hom-Lay Wang, DDS, MSD, PhD; AO Fellow, periodontist and endowed collegiate professor of periodontology at the University of Michigan School of Dentistry in Ann Arbor, MI;

     • Treasurer: Joerg Neugebauer, DDS, PhD; AO Fellow, oral surgeon from Landsberg am Lech, Germany;

     • Immediate Past President: Jay P. Malmquist, DMD; AO Fellow, oral and maxillofacial surgeon from Portland, OR.

Directors

     • Joseph P. Fiorellini, DMD, DMSc; AO Fellow, periodontist and professor of periodontics, University of Pennsylvania School of Dental Medicine in Philadelphia, PA;

     • Jeffrey Ganeles, DMD; AO Fellow and periodontist from Boca Raton, FL;

     • Joseph Y. K. Kan, DDS, MS; Prosthodontist and professor, Department of Restorative Dentistry Implant Dentistry Program at Loma Linda University in Loma Linda, CA;

     • Robert R. Lemke, DDS, MD; Oral and maxillofacial surgeon from San Antonio, TX;

     • Lambert J. Stumpel, DDS; General practitioner from San Francisco, CA;

     • Robert C. Vogel, DDS; General practitioner from Palm Beach Gardens, FL.

About Academy of Osseointegration

With approximately 4,500 members in more than 70 countries, AO is recognized as the premier international association for scientists and professionals interested in osseointegration and implant dentistry. AO serves as a nexus where specialists, generalists and scientists can come together to evaluate emerging research, technology, and techniques; share best practices; and define optimal patient care using timely science and evidence-based methods. Like us on Facebook, follow us on Twitter and Instagram @AcademyOsseo; @AcademyofOsseointegration on Linkedin; and subscribe to us on YouTube.







BIOLASE Announces Regulatory Clearance of Laser Bacterial Reduction Therapy Indication for Epic Hygiene Laser

Posted on March 24, 2020

New Indication for Epic Hygiene Laser Provides Highly Effective, Noninvasive Reduction of Bacterial Level and Inflammation

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, is pleased to announce the Epic Hygiene™ laser received regulatory clearance for Laser Bacterial Reduction (LBR) therapy indication from the Food and Drug Administration (FDA). This new indication now allows for the early management of periodontal disease utilizing laser light energy to reduce bacteria and thus decreasing inflammation and enhancing periodontal health.

The Epic Hygiene laser, designed specifically for dental hygienists by dental hygienists, has continued to arm the hygienist community with more access to the advantages of laser technology since it was first introduced in December 2019. The new indication allows hygienists to perform gentler, highly effective treatments for bacterial reduction and managing periodontal disease.

"We are extremely pleased that this new indication has been cleared by the FDA for the Epic Hygiene Laser," said BIOLASE CEO, Todd Norbe. "With this clearance, we can further expand the types of procedures hygienists can perform, directly aligning with our mission of advancing dentistry across all fields. We also believe this new indication will directly benefit patients by providing a virtually-pain free and faster treatment option."

In addition to the reduction of bacterial level and inflammation, the Epic Hygiene laser has also received clearance for the removal of highly inflamed edematous tissue affected by bacteria penetration of the pocket lining and junctional epithelium.

To learn more about the Epic Hygiene laser, visit go.biolase.com/EpicHygiene or call 855-292-5690.

About BIOLASE, Inc.

BIOLASE, Inc. is a medical device company that is a global market leader in the manufacturing and marketing of proprietary dental laser systems that enable dentists and dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and surgical applications. BIOLASE's laser systems are designed to provide clinically superior, patient-friendly results for many types of common dental procedures compared to those achieved with traditional instruments. BIOLASE has sold over 41,000 laser systems to date in over 80 countries around the world.

For updates and information on Epic Hygiene and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, LinkedIn at www.linkedin.com/company/biolase, Instagram at www.instagram.com/waterlase_laserdentistry, and YouTube at www.youtube.com/biolasevideos.







New President at Amann Girrbach North America

Posted on March 24, 2020

Amann Girrbach has announced a change in its North American Management Team to support the company’s growth strategy. Dave Hancin, former Vice President of Dentsply in Canada and Midwest in Chicago, will take over the role as President for Amann Girrbach North America. Dave assumes his new role, effective immediately.

"I am very pleased to have Dave join our team, and I am convinced that he will take Amann Girrbach North America to the next level of growth in the business of digital dental prosthetics," said Thomas Scherer, CCO (Chief Commercial Officer) of Amann Girrbach AG.







FDLA Symposium Canceled

Posted on March 23, 2020

The Florida Dental Laboratory Association (FDLA) announced that the 2020 Southern States Symposium & Expo has been canceled due to risks presented by the COVID-19 coronavirus. This is the first time the Symposium & Expo has been canceled. The Southern States Symposium & Expo is the highlight of the FDLA's annual offerings and the largest of its live meetings, bringing together hundreds of dental laboratory professionals and service providers from across the nation.

The FDLA says in a statement:

"The decision to cancel was not taken lightly or without careful consideration and consultation.

"The FDLA Board of Directors and staff monitored the COVID-19 situation closely leading up to the cancellation. FDLA's priority in making this decision is the health, safety, and well-being of our members, our staff, our exhibitors, sponsors and speakers. At this time, there are no plans to postpone or reschedule the Symposium & Expo in 2020, due to the uncertainty we are all facing at the moment and the inability to set an accurate timeline. The 2021 Symposium & Expo is planned for May 6 - 8, 2021 at the Renaissance Orlando at SeaWorld.

"To all of our attendees who were planning to attend, we apologize for the inconvenience this cancellation has caused and will offer full refunds for all paid registration fees. You may also roll over your registration fees to the 2021 Symposium & Expo at no additional charge and you will be automatically registered. Our registration staff will contact you with specific instructions on how to request a refund or roll over your registration. Due to the circumstances, we are currently working on how we will do this most efficiently. We ask for your patience as we process a large volume of refunds.

"Exhibit, Sponsorship and Advertising fees can also be applied to the 2021 Symposium & Expo. Our exhibit manager will be in contact regarding the options available for securing your company's exhibit, sponsorship and advertising location for the 2021 Symposium & Expo. 

"If you or your company is currently registered as an attendee, exhibitor, sponsor or advertiser, a separate notice will follow within the next few days with directions on how to roll over your registration for the 2021 Symposium & Expo or request a refund. All refunds should be requested by April 30, 2020. Past April 30, 2020 we will take in good faith that you would like to extend your payment to cover your fees or deposits at the 2021 Symposium & Expo. 

"FDLA will work to preserve the hard work its presenters poured into preparation for this Symposium & Expo and look to provide educational opportunities to our members to assist in the maintenance of CE requirements mandated by the State of Florida and the National Board for Certification for CDT's.

"Hotel Reservations and Cancellations: The Renaissance Orlando at SeaWorld will cancel all reservations made under FDLA's room reservation block. A notice of cancellation will be sent to the email address used when making the reservation. In the event that you do not receive a cancellation notice or you made your hotel reservations outside the FDLA reservation block and/or through a third party hotel booking site, you are encouraged to contact the hotel to cancel your reservation. If you need to contact the hotel regarding your reservation, please call: 407-351-5555.

"We at FDLA feel a deep appreciation for our members and the outpouring of support we have received in the wake of this news. FDLA is a member-run, not-for-profit organization that exists to serve its members, so we appreciate your continued support. Please do not hesitate to contact us with questions, concerns, or requests for topics."







Henry Schein Dental Announces 'COVID-19 and Dentistry' Webinar Series

Posted on March 23, 2020

Company to Provide Education Oral Health Professionals Can Rely On To Ensure Business Continuity During COVID-19 Crisis

Henry Schein, Inc. (Nasdaq: HSIC) today announced a new webinar series to help oral health professionals maintain operational success during the coronavirus outbreak. The free webinar series, entitled “COVID-19 and Dentistry,” will kick off on Monday, March 23 at 2:00 p.m. and will feature Dr. David Reznik, Director of the Oral Health Center of Grady Health System’s Infectious Disease Program, and Gary Severance, DDS, Henry Schein Dental.

To register for the event or to access on-demand, practitioners can visit, https://pages.henryscheindigital.com/COVID19-webinar.

During the webinar, presenters will address the origins of COVID-19 and modes of transmission of COVID-19 in the dental setting; provide clinicians with updated information on implementing infection prevention and control measures; and assess risks for exposure and how to optimize the use of personal protective equipment (PPE) in dental settings to prevent transmission and provide a safe environment for patients and the dental team.

“As a trusted advisor to our customers, Henry Schein is committed to providing the educational resources and business acumen dental professionals can rely on to maintain a successful practice, especially during times of crisis and uncertainty,” said Jonathan Koch, Senior Vice President and Chief Executive Officer, Global Dental Group, Henry Schein. “COVID-19 has created many challenges for our customers, and it is our job to help navigate the public health issues that continue to unfold. This webinar is just one example of the ongoing efforts our company is making to provide relevant and timely education that our customers can quickly implement into their practice and share among their team and patients.”

For ongoing information about what Henry Schein is doing to address this unprecedented situation and the actions the Company is taking to get more product into the hands of those who need it most – health care professionals – please visit: www.henryschein.com/COVID19update.

About  Henry Schein, Inc. 

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 19,000  Team Schein Members  worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based  dental  and  medical  practitioners work more efficiently so they can provide quality care more effectively. These solutions also support  dental laboratories,  government and institutional healthcare clinics,  as well as other alternate care sites. 

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items. 

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 31 countries. The Company's sales from continuing operations reached  $10.0 billion in 2019, and have grown at a compound annual rate of approximately 13 percent since Henry Schein became a public company in 1995. 

For more information, visit Henry Schein at  www.henryschein.com,  Facebook.com/HenrySchein,  and  @HenrySchein on Twitter







NADL Advises on Essential vs Non-Essential

Posted on March 23, 2020

The National Association of Dental Laboratories posted an answer to what it says has been the primary question it has received recently:

"Based on continuing developments by California, New Jersey, Florida, Illinois and New York, and soon to be more state Governors and in some case local county/city ordinances, NADL is receiving questions on how businesses are defined as it relates to essential or non-essential.

"In most of the state Governor executive orders executed thus far, dental offices are mentioned within the essential category, further, most orders use the wording that essential businesses includes but is not limited to hospitals, ambulatory surgery centers, dental offices….key words are includes but is not limited to;

"It is NADL’s belief that in most cases depending on the specific wording in your state, county or city, dental laboratories likely fall into the essential business category (that is if you make the business decision to actually stay open).

"This assessment is based on several arguments:

"1. Dental laboratories according to the U.S. Health and Human Services Office for Civil Rights, under the Health Insurance Portability and Accountability Acts are defined as a "health care provider."

"2. Under the North American Industry Classification Code, NAICS Code 339116: dental laboratories are defined as establishments that are primarily engaged in manufacturing dentures, crowns, bridges, and orthodontic appliances customized for individual application. The parent NAICS code where dental laboratories is NAICS 33911 which is listed under - Medical Equipment and Supplies Manufacturing

"3. In those states where dental laboratories are required to register in order to operate, they pay registration and or license fees to either state Boards of Dentistry and/or state Departments of Health.

"Lastly, if dental offices are allowed to stay open even if it’s just to perform emergency or urgent care, there are specific procedures that have been listed as allowable, that would require the services of a dental laboratory to assist in completion of such work, in order for the dentist to treat the patient.

"This is not meant to construe a legal opinion, as each city, county, state may have different and or more specific wording in the essential business definitions. However, absent dental laboratories not being specifically named as non-essential in city, county, state orders, these factors should provide positive footing if you choose to keep your dental laboratory operational in some capacity."







Nobel Biocare Global Symposium Postponed

Posted on March 23, 2020

Nobel Bloccare announced that the Nobel Biocare Global Symposium, originally scheduled for April 16-18 in Las Vegas, Nevada, has been postponed until early 2021 due to the ongoing spread of the COVID-19 coronavirus.

"The unprecedented circumstances presented by the coronavirus, the increasing health and safety concerns as well as travel restrictions in place have made it impossible for us to hold a global event like the Nobel Biocare Global Symposium at this time,” the company says in a statement. "We believe this decision is in the best interest of the health, safety, and well-being of our customers, employees, and business partners."

Nobel Biocare says it will communicate a specific 2021 date and location for the symposium as soon as available.

Anyone who has already registered will have that registration automatically transferred to count for the 2021 event. If anyone wishes to cancel their participation, Nobel Biocare has relaxed its original cancellation policy and will refund registration fees in full. Questions can be referred to local customer service teams or symposium.lasvegas@nobelbiocare.com.

"At Nobel Biocare we are committed to helping you advance at every level and education is an essential tool to achieve this goal,” the company’s statement says. "On April 16 to 18, we will host a series of virtual educational sessions and make them available to all that had registered to the Nobel Biocare Global Symposium. Access to these virtual educational sessions will be communicated soon.

"We would like to thank you in advance for your understanding of the current circumstances, and we ask for your patience as we work diligently to address questions and provide additional information to our participants and guests."







© 2021 AEGIS Communications | Privacy Policy